Drug Names Will Be Reviewed By FDA Within 90 Days Under PDUFA Timetable
Executive Summary
FDA is establishing timetables for review of proprietary drug names as part of the next cycle of the Prescription Drug User Fee Act
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PS047944
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
PS047944
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.